Vancampfort Davy, Sienaert Pascal, Wyckaert Sabine, De Hert Marc, Stubbs Brendon, Kinyanda Eugene, Probst Michel
Department of Rehabilitation Sciences, KU Leuven - University of Leuven, Leuvensesteenweg 517, B-3070 Kortenberg, Belgium,
Psychiatr Danub. 2016 Jun;28(2):139-45.
The prevalence of metabolic syndrome (MetS) in patients with bipolar disorder is 35 to 40%. It is, however, not established yet whether MetS influences participation in physical activity, walking capacity and global functioning.
Sixty-five patients (36 ♀) received a full-fasting laboratory screening, performed a walk test including self-report of pre- and post-test pain, and completed the International Physical Activity Questionnaire and the Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR16).
Patients with (n=24) and without (n=41) MetS did not significantly differ in age, gender, psychotropic medication doses, physical activity, smoking behaviour and global functioning. In contrast, patients with MetS had a significantly (a) longer illness duration, (b) higher BMI, and (c) lower walking capacity. Moreover, patients with MetS scored significantly higher on the QIDS. Patients with MetS reported more pain before and after the walking test and more dyspnea following 6 minutes of walking, indicating the physical health challenges facing people with bipolar disorder and MetS seeking to engage in physical activity.
The current data give further credence to the importance of interventions promoting the walking capacity in people with bipolar disorder, in particular in these patients at a high risk for cardiovascular diseases.
双相情感障碍患者中代谢综合征(MetS)的患病率为35%至40%。然而,MetS是否会影响身体活动参与度、步行能力和整体功能尚未确定。
65名患者(36名女性)接受了全空腹实验室筛查,进行了一项步行测试,包括测试前和测试后疼痛的自我报告,并完成了国际身体活动问卷和抑郁症状快速自评量表(QIDS-SR16)。
患有(n = 24)和未患有(n = 41)MetS的患者在年龄、性别、精神药物剂量、身体活动、吸烟行为和整体功能方面无显著差异。相比之下,患有MetS的患者(a)病程明显更长,(b)体重指数更高,(c)步行能力更低。此外,患有MetS的患者在QIDS上得分显著更高。患有MetS的患者在步行测试前和测试后报告的疼痛更多,步行6分钟后呼吸困难更严重,这表明双相情感障碍合并MetS且试图参与身体活动的患者面临身体健康挑战。
目前的数据进一步证明了促进双相情感障碍患者步行能力的干预措施的重要性,特别是在这些心血管疾病高危患者中。